0.05Open0.05Pre Close0 Volume7 Open Interest5.00Strike Price0.00Turnover112.80%IV52.57%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1155Delta0.1941Gamma66.20Leverage Ratio-0.0037Theta0.0002Rho7.65Eff Leverage0.0017Vega
CureVac Stock Discussion
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study
in Patients with Resected Glioblastoma
·First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
·Part B expected to include up to 20 patients to generate extended data on safety, tolerabil...
Benzinga· 1 min ago
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
No comment yet